Clustered Regularly Interspaced Short Palindromic Repeats
Intellia’s CRISPR Gene Editing Therapy Shows Promising Results in Reducing HAE Attacks
Intellia Therapeutics, CRISPR Gene Editing, Hereditary Angioedema (HAE), NTLA-2002, Clinical Trials, Gene Therapy, Rare Diseases
Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency
Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy
Agilent Technologies Acquires Biovectra for $925 Million to Enhance Biologics and CRISPR Capabilities
Agilent Technologies, Biovectra, Acquisition, Biologics, CRISPR, Contract Development and Manufacturing Organization (CDMO)
Arc Institute Unveils Revolutionary Bridge Editing Technology for Programmable Genome Design
Bridge editing, genome design, programmable gene editor, DNA strands, Arc Institute, CRISPR, RNA-guided systems, genetic engineering
CRISPR Gene Editing Therapy Can Be Administered Twice, Intellia Study Suggests
CRISPR, gene editing, Intellia Therapeutics, transthyretin amyloidosis, gene therapy, re-dosing
Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy
Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials
Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy
Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data
Preliminary CRISPR-Based HIV Treatment Study Shows Limited Success
CRISPR, HIV, gene editing, treatment, study, curative potential, early study, limited success
Revival of Gene Editing Clinical Trials in China Post CRISPR Baby Scandal
CRISPR baby scandal, China, gene editing, clinical trials, restart, regulations, ethics, CRISPR-Cas9, genetic diseases, biotechnology.
Regeneron Pharmaceuticals Expands Gene Editing Capabilities with Mammoth Biosciences Partnership
Regeneron, Mammoth Biosciences, gene editing, CRISPR, partnership, biotechnology, healthcare, pharmaceuticals, genetic research, therapeutic development.